(Press-News.org) WA, Seattle (August 15, 2013) – Primary results from a new clinical trial show that patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) exhibit greater preservation of C-peptide, a biomarker of islet cell function, compared to controls. Further analyses identified a discrete subset of the treatment group that demonstrated especially robust responses ("responders"), suggesting that these patients could be identified prior to treatment. The trial, entitled "Autoimmunity-Blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes" (AbATE), was conducted by the Immune Tolerance Network (ITN). The results are available online and will be published in the November issue of the journal Diabetes.
The AbATE study, led by Kevan Herold, MD (Yale University), tested teplizumab, which targets the CD3 receptor found on T cells, in patients with new-onset type 1 diabetes. CD3 is required for T-cell activation, which can lead to the destruction of insulin-producing beta cells. A previous ITN study with teplizumab showed that a single course of the drug slowed C-peptide decline in new-onset patients for a year, after which the effects waned. The aim of the AbATE study was to test whether C-peptide preservation could be prolonged by administering two courses of teplizumab, one year apart.
In this open-label, Phase II study, 77 new-onset patients (ages 8 to 30 years old) were randomized to receive either teplizumab or a control. Those in the treatment arm received the scheduled treatment consisting of two 14-day courses of teplizumab, one year apart. Both arms received intensive diabetes care from certified diabetes educators and were followed for two years. The primary endpoint compared C-peptide preservation between the two groups.
After two years, the teplizumab-treated group showed significantly greater preservation of C-peptide (75-percent higher responses compared to the control group).
Further analysis revealed that within the treatment arm two groups of patients could be distinguished based on their C-peptide levels: one group, considered "responders" (22/49), showed very little C-peptide decline over the course of the study (only a 6 percent reduction from baseline), while the "non-responders" (27/49) exhibited a similar rate of C-peptide decline as the control group (less than 40-percent reduction from baseline).
Investigators measured various biomarkers and cell types that might distinguish between these two groups. They found that, at trial entry, "responders" had lower hemoglobin A1c levels (a marker of glucose concentration in the blood) and used less insulin at baseline, compared to "non-responders". Differences in specific T-cell subsets also distinguished between the two groups at baseline, suggesting that immune status might contribute to drug responsiveness. However, further studies will be required to confirm these results.
"This overall approach to identifying characteristics of individuals most likely to respond to therapies shows great promise because the responders in this study experienced a robust and prolonged drug effect," said Dr. Herold. "This type of response has not been seen in other studies of immune therapies."
Type 1 diabetes is a disease marked by immune destruction of insulin-producing beta cells in the pancreas. New-onset patients usually have 20 to 40 percent of their normal beta cell mass remaining, which is still capable of producing insulin. Preserving this remaining mass, even temporarily, could improve long-term clinical outcomes.
Immune modulators, like teplizumab, represent a promising means of inducing tolerance; however, no drug has been shown to prevent or reverse disease, and only a few have temporarily delayed disease progression. The ability to identify a subgroup of patients who may be more responsive to therapy could greatly enhance the clinical use of immune modulators and improve outcomes for those patients. Further analyses with specimens collected from the AbATE study are ongoing to understand the mechanism of response.
###
About The Immune Tolerance Network
The Immune Tolerance Network (ITN) is a research consortium sponsored by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The ITN develops and conducts clinical and mechanistic studies of immune tolerance therapies designed to prevent disease-causing immune responses, without compromising the natural protective properties of the immune system. Visit http://www.immunetolerance.org for more information.
Contact:
Philip Bernstein, PhD
(240) 235 6132
ITNCommunications@immunetolerance.org
Immune Tolerance Network
Office of the Director
1201 Ninth Avenue
Seattle, WA 98101-2795
206-342-6901
ITN type 1 diabetes study identifies subset of patients with strong response to therapy
2013-08-16
ELSE PRESS RELEASES FROM THIS DATE:
Celery, artichokes contain flavonoids that kill human pancreatic cancer cells
2013-08-16
URBANA, Ill. – Celery, artichokes, and herbs, especially Mexican oregano, all contain apigenin and luteolin, flavonoids that kill human pancreatic cancer cells in the lab by inhibiting an important enzyme, according to two new University of Illinois studies.
"Apigenin alone induced cell death in two aggressive human pancreatic cancer cell lines. But we received the best results when we pre-treated cancer cells with apigenin for 24 hours, then applied the chemotherapeutic drug gemcitabine for 36 hours," said Elvira de Mejia, a U of I professor of food chemistry and food ...
UC Davis researchers discover molecular target for the bacterial infection brucellosis
2013-08-16
(SACRAMENTO, Calif.) — UC Davis scientists have uncovered a potential drug target for the development of an effective therapy against the debilitating, chronic form of the bacterial disease brucellosis, which primarily afflicts people in Mediterranean and Middle Eastern countries.
Brucellosis, which affects about 500,000 people worldwide each year, typically is caused by ingestion of unsterilized milk or close contact with body secretions from infected animals. Symptoms include intermittent or irregular fever of variable duration, headache, weakness, profuse sweating, ...
Soft drink consumption linked to behavioral problems in young children
2013-08-16
Americans buy more soft drinks per capita than people in any other country. These drinks are consumed by individuals of all ages, including very young children. Although soft drink consumption is associated with aggression, depression, and suicidal thoughts in adolescents, the relationship had not been evaluated in younger children. A new study by researchers at Columbia University's Mailman School of Public Health, University of Vermont, and Harvard School of Public Health in The Journal of Pediatrics finds that aggression, attention problems, and withdrawal behavior are ...
Soft drinks and behavioral problems in young children
2013-08-16
Cincinnati, OH, August 16, 2013 -- Americans buy more soft drinks per capita than people in any other country. These drinks are consumed by individuals of all ages, including very young children. Although soft drink consumption is associated with aggression, depression, and suicidal thoughts in adolescents, the relationship had not been evaluated in younger children. A new study scheduled for publication in The Journal of Pediatrics finds that aggression, attention problems, and withdrawal behavior are all associated with soft drink consumption in young children.
Shakira ...
Astronomers show galaxies had 'mature' shapes 11.5 billion years ago
2013-08-15
AMHERST, Mass. – Studying the evolution and anatomy of galaxies using the Hubble Space Telescope, an international team of astronomers led by doctoral candidate BoMee Lee and her advisor Mauro Giavalisco at the University of Massachusetts Amherst have established that mature-looking galaxies existed much earlier than previously known, when the universe was only about 2.5 billion years old, or 11.5 billion years ago. "Finding them this far back in time is a significant discovery," says lead author Lee.
The team used two cameras, Wide Field Camera 3 (WFC3), and Advanced ...
Spaceflight alters bacterial social networks
2013-08-15
When astronauts launch into space, a microbial entourage follows. And the sheer number of these followers would give celebrities on Twitter a run for their money. The estimate is that normal, healthy adults have ten times as many microbial cells as human cells within their bodies; countless more populate the environment around us. Although invisible to the naked eye, microorganisms – some friend, some foe – are found practically everywhere.
Microorganisms like bacteria often are found attached to surfaces living in communities known as biofilms. Bacteria within biofilms ...
University of East Anglia research could contain infectious disease outbreaks
2013-08-15
Researchers at the University of East Anglia have identified a rapid response which could help halt infectious diseases such as bird flu, swine flu and SARS before they take hold.
Focusing on the avian flu virus strain H5N1, research published today in the journal PLOS ONE identifies key stages in the poultry trade chain which lead to its transmission to other birds, animals and humans.
High risk times for the disease to spread include during transportation, slaughter, preparation and consumption. It is hoped that the findings and recommendations will help stop the ...
Study reveals much-needed strategy to protect against deadly liver fibrosis
2013-08-15
Chronic liver disease is a leading cause of death in the United States, in part because it often causes the formation of harmful scar tissue—a process known as fibrosis. A study published by Cell Press August 15 in the journal Immunity reveals the central role the immune molecule interleukin 33 (IL-33) plays in the formation of liver fibrosis. The findings suggest that drugs targeting this molecule could serve as a new treatment strategy to protect against liver fibrosis.
"Currently, the therapeutic options for liver fibrosis are limited and not curative," says senior ...
Researchers identify genetic root of mountain sickness
2013-08-15
Exposure to low oxygen levels, such as those present at high altitudes, can wreak havoc on the body. Now researchers reporting August 15 in the American Journal of Human Genetics, published by Cell Press, have uncovered genes that play a role in causing this damage, making them attractive targets for treatments against chronic mountain sickness and other conditions that involve oxygen deprivation.
There are approximately140 million people living permanently at high altitudes, where oxygen levels are low. Many of them have adapted to their environment, but others have ...
Human eye movements for vision are remarkably adaptable
2013-08-15
When something gets in the way of our ability to see, we quickly pick up a new way to look, in much the same way that we would learn to ride a bike, according to a new study published in the Cell Press journal Current Biology on August 15.
Our eyes are constantly on the move, darting this way and that four to five times per second. Now researchers have found that the precise manner of those eye movements can change within a matter of hours. This discovery by researchers from the University of Southern California might suggest a way to help those with macular degeneration ...